The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease

European Journal of Neurology

Volumn 19, Issue 8, 2012, Pages 1100-1107

  Gonzalez Redondo R ^a,b,c   Toledo, J ^b   Clavero, P ^a   Lamet, I ^a   Garcia Garcia D ^b,c   Garcia Eulate R ^a   Martinez Lage P ^d   Rodriguez Oroz M C ^a,b,c,e  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d Fundacion CITA Alzheimer   (Spain)

^e BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

Dementia; Mild cognitive impairment; Parkinson's disease; Silent vascular lesions; White matter hyperintensities

Indexed keywords

CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; TOLCAPONE;

AGED; ARTICLE; BRAIN BLOOD VESSEL; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE COURSE; FEMALE; FOLLOW UP; FRONTAL LOBE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCHELTENS SCALE; SEMANTICS; WHITE MATTER;

AGED; BRAIN; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEMENTIA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84863879243     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03682.x     Document Type: Article

References (37)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392.
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20years. Mov Disord 2008; 23: 837-844.
3. Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol 2009; 118: 587-598.
4. Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007; 78: 641-643.
5. Papapetropoulos S, Villar JM, Mash DC. Is ischemic cerebrovascular disease a risk factor for dementia in patients with Parkinson's disease? Acta Neurol Scand 2006; 113: 353-354.
6. Jellinger KA. Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study. J Neural Transm 2003; 110: 771-778.
7. Schneck MJ. Vascular dementia. Top Stroke Rehabil 2008; 15: 22-26.
8. Rektor I, Goldemund D, Sheardova K, Rektorova I, Michalkova Z, Dufek M. Vascular pathology in patients with idiopathic Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 24-29.
9. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008; 71: 804-811.
10. Burton EJ, Kenny RA, O'Brien J, et al. White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. Stroke 2004; 35: 1270-1275.
11. De Groot JC, De Leeuw FE, Oudkerk M, et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 2002; 52: 335-341.
12. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 2000; 356: 628-634.
13. Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord 1999; 13: 226-231.
14. Barber R, Scheltens P, Gholkar A, et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999; 67: 66-72.
15. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010; 41: 600-606.
16. Slawek J, Wieczorek D, Derejko M, et al. The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol Neurochir Pol 2008; 42: 505-512.
17. Lee SJ, Kim JS, Yoo JY, et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010; 24: 227-233.
18. Beyer MK, Aarsland D, Greve OJ, Larsen JP. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006; 21: 223-229.
19. Dalaker TO, Larsen JP, Dwyer MG, et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. Neuroimage 2009; 47: 2083-2089.
20. Grosset K, Needleman F, Macphee G, Grosset D.. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord. 2004; 19: 1370-1374.
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
22. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-1277.
23. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, et al. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 2009; 24: 1437-1444.
24. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993; 114: 7-12.
25. Huizenga HM, Smeding H, Grasman RP, Schmand B. Multivariate normative comparisons. Neuropsychologia 2007; 45: 2534-2542.
26. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-1748.
27. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102: 355-363.
28. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005; 57: 82-91.
29. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33: 21-25.
30. Nanhoe-Mahabier W, de Laat KF, Visser JE, Zijlmans J, de Leeuw FE, Bloem BR. Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 2009; 5: 533-541.
31. Miranda B, Madureira S, Verdelho A, et al. Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes. J Neurol Neurosurg Psychiatry 2008; 79: 869-873.
32. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004; 61: 1531-1534.
33. Stewart R, Dufouil C, Godin O, et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology 2008; 70: 1601-1607.
34. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 2005; 112: 386-390.
35. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19: 1043-1049.
36. Grambaite R, Selnes P, Reinvang I, et al. Executive dysfunction in mild cognitive impairment is associated with changes in frontal and cingulate white matter tracts. J Alzheimers Dis 2011; 27: 453-462.
37. Santangelo G, Vitale C, Trojano L, et al. Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. Mov Disord 2010; 25: 50-56.